Form 4: Halozyme Director Sells Shares Under 10b5-1 Plan
Insider Transaction Report
A director at Halozyme Therapeutics, Bernadette Connaughton, sold 2,000 shares of common stock for approximately $150,481 through a pre-arranged trading plan.
Summary
- Bernadette Connaughton, a Director of Halozyme Therapeutics, Inc. (HALO), reported the sale of 2,000 shares of common stock.
- The transactions occurred on October 1, 2025.
- The sales were executed under a Rule 10b5-1 trading plan adopted on May 29, 2025.
- 1,500 shares were sold at a weighted average price of $75.086 per share, with prices ranging from $74.64 to $75.55.
- An additional 500 shares were sold at a weighted average price of $75.704 per share, with prices ranging from $75.64 to $75.92.
- Following these transactions, Connaughton beneficially owns 44,952 shares of Halozyme Therapeutics common stock.
Sentiment
Score: 5
Explanation: The filing reports a routine insider stock sale executed under a pre-established 10b5-1 trading plan, which is a common practice for corporate insiders and does not inherently signal positive or negative sentiment regarding the company's future prospects.
Future Outlook
This filing does not contain any forward-looking statements or guidance.
Industry Context
This is a routine insider transaction disclosure and does not provide information related to broader industry trends or competitors.
Stakeholder Impact
- Shareholders: Minor impact as this is a routine, pre-planned insider sale and does not suggest a change in company fundamentals.
Key Dates
| Date | Description |
|---|---|
| 05/29/2025 | Reporting Person adopted a written trading plan in accordance with Rule 10b5-1. |
| 10/01/2025 | Date of earliest transaction (sale of common stock). |
Recommendation
holdThe reported transaction is a pre-scheduled sale by a director under a Rule 10b5-1 plan, which is a common and often routine event for corporate insiders. Such a transaction typically does not reflect a change in the director's view of the company's fundamental value or future prospects, nor does it provide new information that would warrant a change in investment recommendation. Therefore, a 'hold' recommendation is appropriate as this filing alone does not alter the investment thesis.
Keywords
Halozyme Therapeutics, HALO, Form 4, Insider Trading, Stock Sale, Director, 10b5-1 Plan
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.